Sunshine Biopharma, Inc.
SBFM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | 5.7% | -7.2% | – |
| Cost of Goods Sold | – | $0 | $0 | $0 |
| Gross Profit | – | $0 | $0 | $0 |
| % Margin | – | 36.4% | 30.7% | 32.2% |
| R&D Expenses | – | $0 | $0 | -$0 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $0 | $0 | $0 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $0 | $0 | $0 |
| Operating Income | – | -$0 | -$0 | -$0 |
| % Margin | – | -21.8% | -14.6% | -21.2% |
| Other Income/Exp. Net | – | $0 | $0 | -$0 |
| Pre-Tax Income | – | -$0 | -$0 | -$0 |
| Tax Expense | – | -$0 | -$0 | -$0 |
| Net Income | – | -$0 | -$0 | -$0 |
| % Margin | – | -18.8% | -13.3% | -22.5% |
| EPS | – | -7.8 | -0.44 | -0.84 |
| % Growth | – | -1,672.7% | 47.6% | – |
| EPS Diluted | – | -7.8 | -0.44 | -0.84 |
| Weighted Avg Shares Out | – | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | – | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | – | $0 | $0 | $0 |
| EBITDA | – | -$0 | -$0 | -$0 |
| % Margin | – | -20.3% | -13% | -23.1% |